At a glance
ClinicalIndex Comparison RecordN/ACompleted· 50 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observational Pilot Study to Compare the Compliance With and Health Related Quality of Life During Therapy With Standard High-Dose Interferon Alfa (Intron A, HDI) Versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients With Surgically Resected Melanoma
St. Luke's Hospital and Health Network, Pennsylvania·observational·Posted Nov 18, 2013·Updated Feb 13, 2025
In Brief
An observational study for Melanoma. Completed, enrolled 50 participants across 4 sites.
Detailed Summary
To evaluate the compliance with and perceptions of treatment, as well as health-related quality of life (HRQOL) in surgically resected melanoma patients undergoing HDI or PEG IFN therapy.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartDec 2013
Primary CompletionJul 2018
Study CompletionSep 2019
TodayJul 2026
First PostedNov 18, 2013
Enrollment StartDec 1, 2013
Primary CompletionJul 18, 2018
Study CompletionSep 17, 2019
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 12.6 years ago